A phase I ongoing trial (NCT03289533) is evaluating the safety and tolerability of avelumab (anti-PD-L1 mAb) in combination with axitinib (anti-VEGF mAb) as a first line treatment in patients with advanced HCC [75]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.